Weeks Sarah G
Department of Cardiac Sciences, Division of Cardiology, University of Calgary, Calgary, Alberta.
Can J Cardiol. 2008 Jul;24 Suppl B(Suppl B):19B-21B. doi: 10.1016/s0828-282x(08)71025-0.
Nesiritide is an effective therapy in decreasing symptoms and left ventricular filling pressure in patients with acute decompensated heart failure. Health Canada has recently approved this agent for the management of this patient population. The clinical trials to date using nesiritide for the management of decompensated heart failure have been summarized. The clinical experience including indications for use, contraindications, dosage and monitoring has been reviewed. The following should serve as a general guide for the clinical use of nesiritide.
奈西立肽是治疗急性失代偿性心力衰竭患者、减轻症状及降低左心室充盈压的有效疗法。加拿大卫生部最近已批准该药用于治疗这一患者群体。本文总结了迄今为止使用奈西立肽治疗失代偿性心力衰竭的临床试验情况。并对包括适应证、禁忌证、剂量及监测在内的临床经验进行了综述。以下内容可作为奈西立肽临床应用的一般指南。